Panjwani Anusha, Katz Jennifer S, Katz Robert K
Pediatr Ann. 2025 May;54(5):e160-e166. doi: 10.3928/19382359-20250307-02. Epub 2025 May 1.
For infants up to age 12 months, there is an urgent need for protection against respiratory tract infection caused by respiratory syncytial virus (RSV). Nirsevimab (Beyfortus [Sanofi (Bridgewater, NJ), AstraZeneca (Wilmington, DE)], a long-acting monoclonal antibody for infants, and the bivalent RSV prefusion F (RSVpreF) vaccine (ABRYSVO [Pfizer (New York, NY)]) for pregnant women are the current recommendations for protection against RSV. This review summarizes current evidence-based practices for these interventions, highlights recommendations for delivery, and addresses challenges faced by providers during the RSV season. .
对于12个月及以下的婴儿，迫切需要预防由呼吸道合胞病毒（RSV）引起的呼吸道感染。Nirsevimab（Beyfortus[赛诺菲（新泽西州布里奇沃特），阿斯利康（特拉华州威尔明顿）]，一种用于婴儿的长效单克隆抗体）和用于孕妇的二价RSV预融合F（RSVpreF）疫苗（ABRYSVO[辉瑞（纽约州纽约）]）是目前预防RSV的推荐措施。本综述总结了这些干预措施当前基于证据的做法，强调了实施建议，并探讨了RSV流行季节期间医疗服务提供者面临的挑战。
